Published in Dement Geriatr Cogn Disord on August 06, 2004
Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology (2008) 1.74
Subclinical cerebrovascular disease in mild cognitive impairment. Neurology (2009) 1.28
Reliability and validity of an algorithm for the diagnosis of normal cognition, mild cognitive impairment, and dementia: implications for multicenter research studies. Am J Geriatr Psychiatry (2010) 1.27
Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. Am J Geriatr Psychiatry (2011) 1.19
Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 1. Alzheimers Dement (2011) 1.19
Diagnostic accuracy of the RBANS in mild cognitive impairment: limitations on assessing milder impairments. Arch Clin Neuropsychol (2010) 0.88
Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example. Alzheimers Dement (2013) 0.82
Predictive utility of type and duration of symptoms at initial presentation in patients with mild cognitive impairment. Dement Geriatr Cogn Disord (2010) 0.80
Plasma homocysteine and risk of mild cognitive impairment. Dement Geriatr Cogn Disord (2008) 0.80
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol (2007) 5.98
Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron (2005) 3.83
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol (2011) 3.63
Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol (2011) 3.34
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain (2011) 2.76
Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord (2002) 2.56
Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol (2003) 2.56
TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature (2006) 2.56
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med (2006) 2.28
Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem (2005) 2.26
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol (2007) 2.21
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol (2007) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors. Am J Geriatr Psychiatry (2004) 2.15
The effect of a family therapy and technology-based intervention on caregiver depression. Gerontologist (2003) 2.09
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology (2012) 2.06
Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol (2008) 2.03
SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann Neurol (2011) 2.01
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet (2013) 1.97
Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain (2006) 1.86
Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol (2011) 1.84
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Prevalence of dementia in three ethnic groups: the South Florida program on aging and health. Ann Epidemiol (2003) 1.77
Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging (2008) 1.76
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch Neurol (2010) 1.61
Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol (2006) 1.60
Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol (2011) 1.59
Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. Biol Psychiatry (2013) 1.58
Association between SORL1 and Alzheimer's disease in a genome-wide study. Neuroreport (2007) 1.57
Defects in the striatal neuropeptide Y system in X-linked dystonia-parkinsonism. Brain (2013) 1.53
In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci U S A (2003) 1.52
Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J Mol Biol (2002) 1.52
Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol (2010) 1.49
A novel PS1 gene mutation in a large Aboriginal kindred. Can J Neurol Sci (2010) 1.46
SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain (2010) 1.45
The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science (2003) 1.40
The in vivo brain interactome of the amyloid precursor protein. Mol Cell Proteomics (2007) 1.38
RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS. Mol Cell Neurosci (2011) 1.38
Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol (2007) 1.36
APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin.nicastrin complexes. J Biol Chem (2002) 1.34
Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2005) 1.32
Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol (2012) 1.32
Identification of Alzheimer disease-associated variants in genes that regulate retromer function. Neurobiol Aging (2012) 1.30
Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci (2006) 1.29
Reliability and validity of an algorithm for the diagnosis of normal cognition, mild cognitive impairment, and dementia: implications for multicenter research studies. Am J Geriatr Psychiatry (2010) 1.27
Mature glycosylation and trafficking of nicastrin modulate its binding to presenilins. J Biol Chem (2002) 1.26
Nonpharmacological cognitive interventions in aging and dementia. J Geriatr Psychiatry Neurol (2007) 1.25
Semantic interference deficits and the detection of mild Alzheimer's disease and mild cognitive impairment without dementia. J Int Neuropsychol Soc (2004) 1.24
Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol Dis (2006) 1.23
Both the sequence and length of the C terminus of PEN-2 are critical for intermolecular interactions and function of presenilin complexes. J Biol Chem (2004) 1.23
SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS One (2013) 1.23
Stability of different subtypes of mild cognitive impairment among the elderly over a 2- to 3-year follow-up period. Dement Geriatr Cogn Disord (2009) 1.22
Age-at-onset linkage analysis in Caribbean Hispanics with familial late-onset Alzheimer's disease. Neurogenetics (2007) 1.22
Genetic association of CR1 with Alzheimer's disease: a tentative disease mechanism. Neurobiol Aging (2012) 1.19
Defining mild cognitive impairment: impact of varying decision criteria on neuropsychological diagnostic frequencies and correlates. Am J Geriatr Psychiatry (2010) 1.19
Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. Am J Geriatr Psychiatry (2011) 1.19
Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 1. Alzheimers Dement (2011) 1.19
Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.17
Lack of evidence of monomer/misfolded superoxide dismutase-1 in sporadic amyotrophic lateral sclerosis. Ann Neurol (2009) 1.17
ALS mutations in FUS cause neuronal dysfunction and death in Caenorhabditis elegans by a dominant gain-of-function mechanism. Hum Mol Genet (2011) 1.16
The presenilin proteins are components of multiple membrane-bound complexes that have different biological activities. J Biol Chem (2004) 1.15